VYGR Voyager Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VYGR

Price (delayed)

$3.61

Market cap

$218.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.98

Enterprise value

$206.64M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 28

Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation ...

Highlights
Voyager Therapeutics's quick ratio has increased by 40% YoY and by 10% from the previous quarter
The company's debt fell by 18% YoY and by 5% QoQ
Voyager Therapeutics's net income has decreased by 38% YoY but it has increased by 2.6% QoQ
Voyager Therapeutics's EPS has decreased by 35% YoY but it has increased by 2.9% from the previous quarter
The revenue is down by 45% year-on-year and by 10% since the previous quarter
VYGR's gross profit is down by 45% year-on-year and by 10% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.voyagertherapeutics.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of VYGR

VYGR stock price

How has the Voyager Therapeutics stock price performed over time
Intraday
0.28%
1 week
-7.44%
1 month
-6.96%
1 year
8.73%
YTD
-8.14%
QTD
-6.48%

Financial performance

How have Voyager Therapeutics's revenue and profit performed over time
Revenue
$36.49M
Gross profit
$36.49M
Operating income
-$127.42M
Net income
-$116.64M
Gross margin
100%
Net margin
-319.6%
The company's net margin has shrunk by 153% YoY and by 8% QoQ
The operating margin has plunged by 130% YoY and by 7% from the previous quarter
The revenue is down by 45% year-on-year and by 10% since the previous quarter
VYGR's gross profit is down by 45% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does VYGR's price correlate with its fundamentals

Growth

What is Voyager Therapeutics's growth rate over time

Valuation

What is Voyager Therapeutics stock price valuation
VYGR P/E details
P/E
N/A
P/B
1.24
P/S
5.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.66
Voyager Therapeutics's EPS has decreased by 35% YoY but it has increased by 2.9% from the previous quarter
VYGR's equity is down by 36% year-on-year and by 11% since the previous quarter
VYGR's price to book (P/B) is 31% lower than its 5-year quarterly average of 1.8 but 13% higher than its last 4 quarters average of 1.1
The revenue is down by 45% year-on-year and by 10% since the previous quarter
VYGR's price to sales (P/S) is 37% more than its 5-year quarterly average of 4.3 but 7% less than its last 4 quarters average of 6.3

Efficiency

How efficient is Voyager Therapeutics business performance
Voyager Therapeutics's ROS has plunged by 154% YoY and by 8% from the previous quarter
Voyager Therapeutics's return on assets has shrunk by 104% YoY and by 9% QoQ
VYGR's return on equity has dropped by 104% year-on-year and by 9% since the previous quarter
Voyager Therapeutics's ROIC has plunged by 82% YoY and by 7% from the previous quarter

Dividends

What is VYGR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VYGR.

Financial health

How did Voyager Therapeutics financials performed over time
The total liabilities has contracted by 43% YoY and by 19% from the previous quarter
Voyager Therapeutics's quick ratio has increased by 40% YoY and by 10% from the previous quarter
The company's debt is 80% lower than its equity
VYGR's equity is down by 36% year-on-year and by 11% since the previous quarter
VYGR's debt to equity is up by 33% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.